This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Prognosis and management of adult wild type gastrointestinal stromal tumours (GISTs): A pooled analysis and review of literature
A pooled review was performed to determine survival in adult WT GIST (Wild Type GastroIntestinal Stromal Tumours) and compare the same with pediatric WT GISTs. Electronic databases were searched using the terms “Wild type” AND “GIST”. Eighty-two adult patients from 14 studies were included in the pooled analysis. Cumulative survival was greater than 50% in both age groups, hence medial survival could not be computed. Mean survival in adults was 15.7 years ± 0.78 and in children was 18.8 years ±  1.3 (p = 0.241).
Source: Surgical Oncology - May 9, 2016 Category: Surgery Authors: N.R. Bhatt, D. Collins, P. Crotty, P.F. Ridgway Source Type: research

Cost-Effectiveness Analysis Of Regorafenib In Gastrointestinal Stromal Tumours In England Using Crossover Adjustment Methods
A placebo-controlled randomised trial (GRID) compared regorafenib and best supportive care (BSC) to BSC alone in the treatment of metastatic/unresectable gastrointestinal stromal tumours in patients previously treated with imatinib and sunitinib. Regorafenib significantly improved progression-free survival; however, overall survival (OS) did not differ significantly between arms. By 8th June 2015, 87.9% of BSC patients switched to regorafenib post-progression; switching occurred at a median of 0.9 months after randomisation.
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: A Pitcher, E Grabbi, M Madin-Warburton, S Vadgama Source Type: research

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
k, Yuichiro Doki, Seock-Ah Im, Seiichi Hirota, Seokyung Hahn, Toshirou Nishida & Yoon-Koo Kang
Source: British Journal of Cancer - June 27, 2017 Category: Cancer & Oncology Authors: Yukinori Kurokawa Han-Kwang Yang Haruhiko Cho Min-Hee Ryu Toru Masuzawa Sook Ryun Park Sohei Matsumoto Hyuk-Joon Lee Hiroshi Honda Oh Kyoung Kwon Takashi Ishikawa Kyung Hee Lee Kazuhito Nabeshima Seong-Ho Kong Toshio Shimokawa Jeong-Hwan Yook Yuichiro Dok Tags: GIST imatinib neoadjuvant preoperative stomach gastric Source Type: research

Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting
Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on ...
Source: BMC Medicine - August 22, 2017 Category: Internal Medicine Authors: Anna Maria Frezza, Silvia Stacchiotti and Alessandro Gronchi Tags: Commentary Source Type: research

Texture analysis of CT images in predicting malignancy risk of gastrointestinal stromal tumours
To explore the role of texture analysis of computed tomography (CT) images in predicting the malignancy risk of gastrointestinal stromal tumours (GISTs).
Source: Clinical Radiology - September 30, 2017 Category: Radiology Authors: S. Liu, X. Pan, R. Liu, H. Zheng, L. Chen, W. Guan, H. Wang, Y. Sun, L. Tang, Y. Guan, Y. Ge, J. He, Z. Zhou Source Type: research

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib
This study explores the relationship of single nucleotide polymorphisms (SNPs) in genes related to imatinib pharmacokinetics and pharmacodynamics and PFS in imatinib-treated patients with advanced GIST.
Source: European Journal of Cancer - October 18, 2017 Category: Cancer & Oncology Authors: Michiel C. Verboom, Jacqueline S.L. Kloth, Jesse J. Swen, Tahar van der Straaten, Judith V.M.G. Bov ée, Stefan Sleijfer, Anna K.L. Reyners, Ron H.J. Mathijssen, Henk-Jan Guchelaar, Neeltje Steeghs, Hans Gelderblom Tags: Original Research Source Type: research

Oncogenic kit signalling on the golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours
In this study, we show that in GIST, 2-methylcoprophilinamide (M-COPA, also known as “AMF-26”), an inhibitor of biosynthetic protein trafficking from the endoplasmic reticulum (ER) to the Golgi, suppresses Kit autophosphorylation at Y703/Y721/Y730/Y936, resulting in blockade of oncogenic signalling.
Source: Cancer Letters - November 28, 2017 Category: Cancer & Oncology Authors: Yuuki Obata, Keita Horikawa, Isamu Shiina, Tsuyoshi Takahashi, Takatsugu Murata, Yasutaka Tasaki, Kyohei Suzuki, Keita Yonekura, Hiroyasu Esumi, Toshirou Nishida, Ryo Abe Tags: Original Articles Source Type: research

Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours
ConclusionsThe nomograms were able to more accurately predict 3- and 5-year OS and CSS of patients with GISTs than were existing models.
Source: European Journal of Surgical Oncology (EJSO) - July 21, 2018 Category: Surgery Source Type: research

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee and EURACAN PMID: 30188977 [PubMed - as supplied by publisher]
Source: Ann Oncol - September 5, 2018 Category: Cancer & Oncology Authors: Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni Tags: Ann Oncol Source Type: research

Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively
ConclusionsThis radiomics nomogram predicted the malignant potential of GISTs with excellent accuracy and may be used as an effective tool to guide preoperative clinical decision-making.Key Points• CT-based radiomics model can differentiate low- and high-malignant-potential GISTs with satisfactory accuracy compared with subjective CT findings and clinical indexes.• Radiomics nomogram integrated with the radiomics signature, subjective CT findings and clinical indexes can achieve individualised risk prediction with improved diagnostic performance.• This study might provide significant and valuable background informati...
Source: European Radiology - January 31, 2019 Category: Radiology Source Type: research

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
British Journal of Cancer, Published online: 23 May 2019; doi:10.1038/s41416-019-0487-5Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Source: British Journal of Cancer - May 22, 2019 Category: Cancer & Oncology Authors: C ésar Serrano Adri án Mariño-Enríquez Derrick L. Tao Julia Ketzer Grant Eilers Meijun Zhu Channing Yu Aristotle M. Mannan Brian P. Rubin George D. Demetri Chandrajit P. Raut Ajia Presnell Arin McKinley Michael C. Heinrich Jeffrey T. Czaplinski Ewa Si Source Type: research

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
This document is a summary of the French Intergroup guidelines regarding the management of gastrointestinal stromal tumours (GISTs) updated in December 2018.
Source: Digestive and Liver Disease - August 2, 2019 Category: Gastroenterology Authors: Bruno Landi, Jean-Yves Blay, Sylvie Bonvalot, Mathilde Brasseur, Jean Michel Coindre, Jean Fran çois Emile, Vincent Hautefeuille, Charles Honore, Eric Lartigau, Georges Mantion, Marc Pracht, Axel Le Cesne, Michel Ducreux, Olivier Bouche, on behalf of the Tags: Guidelines Source Type: research

Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours  participating in the EORTC STBSG 62024 adjuvant imatinib study
EORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III  randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease after surgery in 908 patients from 11 countries participated. As surgical treatment aspects (tumour rupture and incomplete resection) contribute to the risk o f recurrence, the data of primary surgery were reviewed.
Source: European Journal of Cancer - August 30, 2019 Category: Cancer & Oncology Authors: Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo Casali Tags: Original Research Source Type: research

Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
British Journal of Cancer, Published online: 14 October 2019; doi:10.1038/s41416-019-0596-1Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
Source: British Journal of Cancer - October 13, 2019 Category: Cancer & Oncology Authors: Changhoon Yoo Yeon-mi Ryu Sang-Yeob Kim Jihun Kim Chan Young Ock Min-Hee Ryu Yoon-Koo Kang Source Type: research

Non-gastrointestinal stromal tumours soft tissue sarcomas: an update.
Authors: Matos GDR, de Camargo VP, Munhoz RR, de Castro G Abstract Soft tissue sarcomas (STS) encompass a diverse family of neoplasms of mesenchymal origin, marked by significant heterogeneity in terms of physiopathology, molecular characterisation, natural history and response to different therapies. This review aims to summarise the current strategies for the management of patients with STS, including surgery, systemic treatments and radiation therapy, along with considerations applicable to the most frequent subtypes, as well as particularities associated with less common and specific histologies. It also provid...
Source: Ecancermedicalscience - October 26, 2019 Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research